Management of Suspected Essential Thrombocythemia

Diagnostic Confirmation and Risk Stratification

The National Comprehensive Cancer Network recommends formal diagnostic workup for essential thrombocythemia, including JAK2/CALR/MPL mutation testing and bone marrow biopsy, followed by risk stratification using the revised IPSET-Thrombosis score to determine if cytoreductive therapy is warranted in patients with suspected essential thrombocythemia and chronic thrombocytosis 1, 2
The presence of JAK2 V617F mutation increases thrombotic risk and influences risk stratification in essential thrombocythemia patients 2

The National Comprehensive Cancer Network guidelines recommend low-dose aspirin (81-100 mg daily) as the treatment of choice for microvascular occlusive symptoms in essential thrombocythemia patients, regardless of platelet count in the range of 447-589 × 10⁹/L 1
Cytoreductive therapy is indicated for high-risk essential thrombocythemia patients (prior thrombosis or age >60 with JAK2 mutation) to reduce thrombotic complications, with hydroxyurea as the first-line cytoreductive agent 1, 2
Target platelet count should be <400 × 10⁹/L while monitoring for cytopenias in essential thrombocythemia patients on cytoreductive therapy 2

Regular complete blood count monitoring is essential to track platelet trends and assess response to any initiated therapy in essential thrombocythemia patients 2
Monitoring for signs of thrombosis, bleeding complications, and progression of microvascular symptoms is crucial in essential thrombocythemia patients, according to the National Comprehensive Cancer Network guidelines 4, 1